Oragenics (NYSE:OGEN) Now Covered by Analysts at StockNews.com

StockNews.com initiated coverage on shares of Oragenics (NYSE:OGEN) in a research note released on Friday morning. The firm issued a sell rating on the stock.

Oragenics Stock Performance

OGEN stock opened at $0.22 on Friday. The stock’s 50 day simple moving average is $0.28 and its 200 day simple moving average is $0.33. The company has a market cap of $4.64 million, a P/E ratio of -0.03 and a beta of 0.85. Oragenics has a fifty-two week low of $0.21 and a fifty-two week high of $3.43.

Oragenics Company Profile

Oragenics, Inc, a development-stage company, engages in the research and development of antibiotics for infectious diseases in the United States. The company engages in the development and commercialization of NT-CoV2-1, an intranasal vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus.